COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn BHBH FPVFPV FLVFLV PVP-IPI REGNR2 LY-CoVLY RMDRMD
LY-CoV study #2 of 5
10/28 Early treatment study
Chen et al., NEJM, doi:10.1056/NEJMoa2029849 (Peer Reviewed)
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Source   PDF   Share   Tweet
Interim analysis of the BLAZE-1 phase 2 trial of outpatients showing lower hospitalization or ER visits (1.6% versus 6.3%), and improvements in symptoms and viral load compared to placebo.
NCT04427501

Chen et al., 10/28/2020, Randomized Controlled Trial, USA, North America, peer-reviewed, 12 authors.
risk of hospitalization, 74.3% lower, RR 0.26, p = 0.02, treatment 5 of 309 (1.6%), control 9 of 143 (6.3%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 5 studies
Please send us corrections, updates, or comments.
Submit